A Phase I, Combination, Immunologic Study of LTX-315 as Adjunct to GV1001 in Patients Following Curative Surgery for Carcinoma.

Trial Profile

A Phase I, Combination, Immunologic Study of LTX-315 as Adjunct to GV1001 in Patients Following Curative Surgery for Carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Mar 2015

At a glance

  • Drugs LTX 315; Tertomotide
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Lytix Biopharma
  • Most Recent Events

    • 14 Feb 2012 Status changed from recruiting to completed according to ClinicalTrials.gov.
    • 07 Jun 2011 Planned end date changed from 1 Aug 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.
    • 07 Dec 2010 First patient treated, according to a Lytix Biopharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top